bezafibrate / Generic mfg. - LARVOL DELTA

Targeting mitochondrial dysfunction across the lifespan: Role of bezafibrate in neurodevelopment and neurodegeneration. (PubMed, Neural Regen Res) - No abstract available

Journal • CNS Disorders • Metabolic Disorders

A bezafibrate bearing Pt(IV) prodrug triggers ferroptosis via modulating lipid metabolism in lung cancer cells. (PubMed, J Biol Inorg Chem) - No abstract available

Journal • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor

Mechanistic Dichotomy in Sulfate Radical Anion-Mediated Oxidative Synthesis of Activated N-Hydroxysuccinimide Esters. (PubMed, J Org Chem) - "The synthetic utility was demonstrated by the preparation of marketed drugs, including moclobemide, procainamide, acecainide, and bezafibrate, with moclobemide further synthesized on a 100 g scale, highlighting the practicality and industrial relevance of the process. The results suggest that the generation and subsequent radical-radical coupling of acyl and succinimide-N-oxyl radicals constitute the most favorable pathway, while alternative radical and cationic routes may also contribute under reaction conditions. This study not only advances an efficient and scalable amide synthesis but also broadens the mechanistic understanding of sulfate radical anion reactivity in aromatic systems."

Journal

Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial. (PubMed, Hepatol Commun) - "BZF decreased cholestasis markers in survivors of BA with native livers, indicating its potential as an alternative to delayed liver transplantation for this population."

Journal • P2 data • Cholestasis • Hepatology • Liver Failure • Nephrology • Renal Disease • Transplantation

Pharmaceuticals, Pesticides, and Poly- and Perfluoroalkyl Substances at Surface Water Occurrence Levels-Impact of Compound Specific Physicochemical Properties on Nanofiltration and Reverse Osmosis Processes. (PubMed, Membranes (Basel)) - "Size exclusion and electrostatic interactions were identified as the primary removal mechanisms, with hydrophobic interactions having a lower impact, particularly for carbamazepine, bezafibrate, and perfluorooctane sulfonic acid (PFOS). Addition of sodium chloride (3 g L-1) decreased rejection of most negatively charged compounds due to suppression of membrane surface charge, although clarithromycin and ofloxacin exhibited improved rejection. Presented results provide fundamental insight into compound-specific membrane rejection and highlight the importance of membrane-solute interactions under environmentally realistic conditions. The results support further optimization of NF and RO for targeted compound rejection and provide a baseline for data-driven membrane process modeling."

Journal

Retraction Notice: Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. (PubMed, J Epilepsy Res) - "[This retracts the article on p. 45 in vol. 4, PMID: 25625088.]."

Journal • CNS Disorders • Epilepsy

Targeting PGC-1α axis Rescues Aberrant Development from Thyroid Hormone Defect in Brain Organoids. (PubMed, Pharmacol Res) - "Most importantly, pharmacological stimulation of the PGC-1α axis with Nicotinamide Riboside or Bezafibrate rescues mitochondrial bioenergetics and neuronal development, effectively correcting aberrant brain organoid maturation despite T3 deficiency. These findings reveal for the first time the role of T3 in supporting neurodevelopment via activation of mitochondrial β-oxidation and OXPHOS biogenesis, and identify the PGC-1α axis as a promising therapeutic avenue for otherwise intractable disorders linked to thyroid hormone deficiency."

Journal • Developmental Disorders • Mental Retardation • PPARGC1A

Investigating the therapeutic mechanisms of dental pulp stem cells in Parkinson's disease: A bioinformatics-based multi-omics analysis. (PubMed, Biochem Biophys Res Commun) - "Molecular docking further demonstrated strong predicted binding affinities for MGAT1 with SRC kinase inhibitor II (-8.58 kcal/mol), ARRB2 with bezafibrate (-5.19 kcal/mol), and COL15A1 with ruxolitinib (-6.32 kcal/mol). In vivo qPCR analysis in the PD rat model confirmed downregulation of ARRB2 and MGAT1 and upregulation of COL15A1 (p < 0.05), supporting the bioinformatics findings. Overall, this multi-level analysis highlights potential mechanisms between DPSCs and PD, and identifies candidate genes and drug targets that may inform future therapeutic strategies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study. (PubMed, Am J Gastroenterol) - "In this real-world nationwide study, the one-year fibrate discontinuation rate was substantial. However off-label use of bezafibrate was associated with reductions in the biochemical markers of cholestasis in PBC, which were associated with clinical outcome in this setting of second line therapy."

Journal • Real-world evidence • Cholestasis • Hepatology • Immunology • Liver Failure • Primary Biliary Cholangitis • Transplantation

Development of a methodology in an automated system for analysis of naproxen and bezafibrate in in-situ formation using a deep eutectic solvent by liquid chromatography. (PubMed, J Chromatogr A) - "The precision results were lower than 15.9% and recoveries ranged from 71 to 102%. The greenness of the methodology was confirmed using the AGREEprep tool, demonstrating that the proposed strategy offers a sustainable, selective, and high-throughput alternative for the determination of emerging pharmaceutical contaminants in aquatic environments."

Journal

mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes. (PubMed, Pharmacogenomics J) - "Notably, bezafibrate, a PPAR pan-agonist, demonstrated substantial genetic overlap with T2D loci, supporting its potential in metabolic disease. This study introduces a genetically informed pipeline for drug repurposing based on multi-trait gene set analysis."

Journal • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus • KCNQ1OT1 • PPARG

Targeting PRDM1 to Enhance CAR T Cell Therapy Against Diffuse Large B Cell Lymphoma (DLBCL) (ASH 2024) - "From a translational perspective, we assessed the potential synergistic effects of a PGC1α agonist, bezafibrate, with CAR T cells...Building upon a correlation between PRDM1 expression and CAR T cell dysfunction, we aim to pioneer the use of PRDM1 and/or its target genes as novel biomarkers for predicting clinical responses of r/r DLBCL patients to CAR T cell therapy. Our endeavors will better elucidate the mechanisms by which PRDM1 determines the fates of clinical CAR T cell products and the translational potential of targeting PRDM1/PRDM1-mediated pathways to generalize the application of CAR T cell therapy against cancers."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD8 • PPARGC1A • PRDM1

Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis (ISPOR-EU 2025) - "Pruritus is a common symptom in PBC, especially in female patients. However, treatment patterns in Germany show decreasing reliance on cholestyramine, with increasing use of alternative therapies."

Reimbursement • US reimbursement • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - "Sulfite administration decreased Fluoromyelin and myelin basic protein staining, indicating myelin alterations. Sulfite also increased the staining of NG2, a protein marker of oligodendrocyte progenitor cells, suggesting the induction of remyelination. In line with these findings, sulfite also reduced the viability of MO3.13 cells, a cell line with oligodendroglial characteristics."

Oxidative stress • Preclinical • CNS Disorders • Epilepsy • Genetic Disorders • Inflammation • Solid Tumor • HMOX1 • IL10 • IL1B • IL6 • MBP

Investigating antidiabetic drug targets as potential therapeutic modulators for schizophrenia. (PubMed, Psychopharmacology (Berl)) - "Antidiabetic drugs may possess therapeutic potential in schizophrenia by modulating specific drug-related pathways.These findings provide new theoretical support for the selection of ADs in patients with schizophrenia comorbid with diabetes, and also offer new insights for the future development of APs."

Journal • CNS Disorders • Diabetes • Metabolic Disorders • Psychiatry • Schizophrenia • KCNJ11 • RXRB

Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR γ activity. (PubMed, Int Immunopharmacol) - "Initially, molecular docking was performed using a panel of fibrate-class compounds (including pemafibrate, bezafibrate, fenofibrate, gemfibrozil, and clofibrate) against the ligand-binding domain of PPAR-γ (PDB ID: 7WGO). These findings suggest that bezafibrate, selected through integrative computational and pharmacological screening, effectively ameliorates experimental autoimmune arthritis via PPAR-γ activation. This highlights its promise as a repurposed therapeutic candidate and warrants further investigation."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL1B • IL6 • TNFA

A dispersion-corrected DFT calculation on the drug delivery of Bezafibrate using pectin biopolymer. (PubMed, Sci Rep) - "Additionally, the recovery time was estimated to analyze the interaction mechanism between the bezafibrate drug and pectin, as well as its effect on drug release. These insights contribute to the understanding of Pectin's polysaccharides in biomedical applications, particularly for advanced drug delivery systems."

Journal

Novel Drug Molecules for Atherosclerosis from Ginkgo biloba, an Endangered Himalayan Herb, Via Pharmacoinformatics Approaches. (PubMed, Curr Pharm Biotechnol) - "The findings highlight the multi-target therapeutic potential of Isoginkgetin in mitigating the initiation and progression of atherosclerosis."

Journal • Atherosclerosis • Cardiovascular • Inflammation • Metabolic Disorders • CYP19A1 • PACERR • PTGS2

Fibrates as an Adjunct Therapy in Primary Biliary Cholangitis: A Propensity-Matched Analysis of Major Adverse Cardiovascular Events (ACG 2025) - "Cohort A was also prescribed an additional fibrate (fenofibrate, gemfibrozil, bezafibrate, or ciprofibrate); Cohort B received UDCA monotherapy. The fibrate cohort had higher baseline total cholesterol (212.7 ± 90.0 vs 191.5 ± 66.7 mg/dL, p 0.05). Over a five-year period, fibrate and UCDA-only patients did not differ in the incidence of MACE (HR 1.09, 0.91-1.29, p = 0.35), no individual MACE components (all p-values > 0.05) , or all-cause mortality (HR 0.92, 0.73-1.16, p = 0.47). In this large U.S. real-world cohort, adding a fibrate to UDCA did not significantly increase MACE or mortality despite a more atherogenic lipid profile at baseline. The modest, nonsignificant excess in event rates likely reflects residual confounding from patients selected for fibrate therapy because of dyslipidemia."

Adverse events • Cardiovascular • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hepatology • Hypertension • Immunology • Metabolic Disorders • Myocardial Infarction • Primary Biliary Cholangitis

Fibrates as an Adjunct Therapy in Primary Biliary Cholangitis Is Associated With Lower Hospitalization and Healthcare Utilization: A Propensity-Matched Analysis (ACG 2025) - "Introduction: Fibrates is considered a second line agent for primary biliary cholangitis (PBC) and improves biochemical responses in PBC patients not responding to ursodeoxycholic acid (UDCA)...Cohort A was also prescribed additional fibrate (fenofibrate, gemfibrozil, bezafibrate, or ciprofibrate); Cohort B was on UDCA monotherapy... Over five years, fibrate patients were less likely to develop spontaneous bacterial peritonitis (2.0 % vs. 1.1%, HR 0.52, 0.29-0.92), and had fewer incidences of all-cause hospitalizations ( 26.7 % vs. 21.8%, HR 0.75, 0.65-0.86)."

Clinical • HEOR • CNS Disorders • Fatigue • Fibrosis • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Musculoskeletal Diseases • Osteoporosis • Primary Biliary Cholangitis • Rheumatology • Solid Tumor

Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. (PubMed, Drug Metab Dispos) - "To address the challenge of cellular CYP8B1 inhibition characterization, this work developed a pharmacologically optimized HepG2 cells model using triiodothyronine-dexamethasone-bezafibrate (TDB) induction, which significantly enhances the 12α-hydroxylation activity along the acidic pathway of BA biosynthesis in HepG2 cells...Econazole acted as a relatively selective CYP8B1 inhibitor with a cellular half-maximal inhibitory concentration of 0.31-0.45 μM, tioconazole and posaconazole dually inhibited CYP8B1 and sterol 27-hydroxylase (CYP27A1), itraconazole and voriconazole primarily inhibited CYP27A1, and fluconazole showed no activity toward either enzyme. This study provides the first direct evidence that CYP8B1 participates in cholic acid synthesis via the acidic pathway and establishes a high-throughput cellular platform for screening CYP8B1 inhibitors, revealing azoles as effective modulators of this pathway. SIGNIFICANCE STATEMENT: Optimized HepG2 model using a..."

Journal • Metabolic Disorders • APOA1 • CYP27A1 • CYP8B1

Investigating the Mechanisms of Mitochondrial Dysfunction in Ischemic Stroke and Predicting Therapeutics Through Machine Learning and Integrated Bioinformatics. (PubMed, Curr Med Chem) - "Our findings underscore mitochondrial dysfunction not only as a critical factor in IS pathogenesis but also as a viable therapeutic target. The identified MRG signature presents potential for clinical application in diagnostic and pharmacological strategies aimed at ameliorating ischemic injury. This study highlights the translational significance of systems biology approaches within cerebrovascular medicine, warranting further mechanistic exploration of mitochondrial-immune interactions in stroke pathology."

Journal • Cardiovascular • CNS Disorders • Ischemic stroke • Metabolic Disorders • Vascular Neurology • ACSL1 • ALDH2 • CD8 • PDK4